The U.S. Food and Drug Administration on Thursday approved Amgen Inc.’s cholesterol-lowering drug Repatha, a promising medicine that could reduce heart disease and create billions of dollars in sales for the Thousand Oaks biotech giant. Repatha is an injected medicine that Amgen said can reduce LDL, the so-called “bad” cholesterol, by 50% or more. LDL is a significant risk factor for heart attack and stroke. Map and database: Find Obamacare doctors in California Developed by Amgen’s scientists, Repatha is the second in a new class of drugs that lower cholesterol by blocking a protein called PCSK9 that interferes with the body’s ability to remove LDL. FDA officials said they... More